HROWHarrow, Inc.
Price
-34%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market against it.
We are a leading provider of ophthalmic disease management solutions in North America, and were founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, we have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Harrow, Inc. (HROW) reported revenue of $71M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 71% and net loss of $17M. For the full year FY2025, revenue was $272M (+36% year on year) and net income −$5.1M. Its largest product in Q2 2026 was Product Sales Net at $71M, 100% of the disclosed total, well ahead of Other at 0.1%. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026As previously disclosed, on August 3, 2026, Harrow, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Original Purchase Agreement") with Viatris Inc. ("Viatris") relating to the acquisition of TYRVAYA ® (varenicline solution) nasal spray 0.03 mg ("TYRVAYA"), a cholinergic agonist indicated for the …Material agreement entered · Form 8-K
- Sep 4, 2026Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. (the “Company”)Director or officer change · Form 8-K
- Aug 10, 2026Announces Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $70.7MThe company’s own SEC segment disclosure.
- Product Sales Net$70.6M100%
- Other$90.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #22 of 41 by RyuScore